Difference between revisions of "Aminocaproic acid (Amicar)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| Line 24: | Line 24: | ||
[[Category:Fibrinolysis inhibitors]] | [[Category:Fibrinolysis inhibitors]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1964]] |
Revision as of 18:53, 30 July 2018
General information
Class/mechanism: Inhibits fibrinolysis by inhibiting plasminogen activators and via antiplasmin activity.[1][2][3]
Route: IV, PO
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Also known as
- Generic names: 6-aminohexanoic acid, epsilon aminocaproic acid, ε-aminocaproic acid, ε-Ahx
- Brand name: Amicar